Machine signal
Active cluster sell — 5 distinct insiders, $3.5M, window ends Sep 10, 2026.
Figures computed from official regulatory filings — .
Analysttarget 42.36 USD (+52%) · consensus 4.83/5 · 11 buy · 1 hold · 0 sell
Ownershipinsiders 7.18% · institutions 92.4% · short 13.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Amylyx Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
16 buys136 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| FRATES JAMES M | Sell | $34.6K | SEC |
| Mazzariello Gina | Sell | $309.1K | Unusual size | SEC |
| Klee Justin B. | Sell | $47.7K | SEC |
| Bedrosian Camille L | Sell | $256K | SEC |
| Cohen Joshua B | Sell | $950K | SEC |
| Cohen Joshua B | Sell | $30.5K | SEC |
| FRATES JAMES M | Sell | $315.2K | SEC |
| Klee Justin B. | Sell | $932.6K | SEC |
| Bedrosian Camille L | Sell | $68.9K | SEC |
| Mazzariello Gina | Sell | $366.7 | SEC |
| Firestone Karentrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Firestone Karentrack record | Exercise | $44K | SEC |
| Firestone Karentrack record | Exercise | $126.3K | SEC |
| Firestone Karentrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mazzariello Gina | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FRATES JAMES M | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cohen Joshua B | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klee Justin B. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bedrosian Camille L | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mazzariello Gina | Sell | $264.1K | Unusual size | SEC |
| Mazzariello Gina | Sell | $274.7K | Unusual size | SEC |
| Zeiher Bernhardt G | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FONTEYNE PAUL R. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MILNE GEORGE M JRtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Quimi Daphnetrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |